Home > News Center > Iran Medical Device Registration: 20 FAQs on FDO Rules, IRC Codes and Import Practice (2026)

Iran Medical Device Registration: 20 FAQs on FDO Rules, IRC Codes and Import Practice (2026)

Nov 12, 2026 Registration Insights 0 views

Market access for medical devices in Iran cannot be simplified into obtaining a single registration certificate. Companies need to handle foreign manufacturer representative registration, Iranian local importer qualifications, the product registration code (IRC), import licenses, commodity identification and traceability, customs clearance, and post-market obligations at the same time. Product registration and the license required for each import are not the same matter, and obtaining an IRC does not automatically mean a product can be imported or cleared through customs.

This article has been verified and revised based on retrievable Iranian regulatory texts, public materials from the Iranian competent authority and the food and drug departments of medical universities, and public rules of the US Treasury’s OFAC. Iranian regulations are subject to their official Persian texts and the directives currently issued by the competent authority; for fees, review timelines and case-specific procedures that cannot be confirmed through public channels, this article makes no unsupported definitive commitments.

Part 1: Regulatory Framework and Legal Basis

Q1: Which authority regulates medical devices in Iran?

Answer: The competent authority for medical device regulation in Iran is the Iran Food and Drug Administration (IFDA), which operates under the Ministry of Health and Medical Education (MOHME). Specific medical device matters are handled by the General Directorate of Medical Equipment and Supplies under the IFDA, commonly known in the industry as IMED, covering the manufacture, import, registration, distribution and post-market oversight of medical devices.

The Technical Committee is established within the medical device regulatory system and undertakes responsibilities such as reviewing technical rules, handling special matters, setting qualification requirements for technical personnel and revoking registration codes. It is not an independent regulator parallel to the IFDA.

For certain Class A and B products, the review or licensing work may be delegated by the competent authority to the food and drug departments of medical universities, but these remain within the IFDA regulatory system.

Official inquiry portals:

  • IMED: https://www.imed.ir/
  • Iran Food and Drug traceability system TTAC: https://www.ttac.ir/

Q2: What are the main regulations governing medical device registration in Iran?

Answer: The third edition of the Medical Device Registration Guideline (2018) cannot be cited alone as the full set of current regulatory bases. At present, the following levels should be understood at a minimum:

  • Parent law: the Law on the Regulation of Medical, Pharmaceutical and Food and Beverage Affairs and its subsequent amendments.
  • Sector activity regulations: the Regulations on Activities in the Field of Medical Equipment, approved on 1 Dey 1397 of the Iranian calendar, which mainly governs entity registration, product registration, manufacture, import, distribution, after-sales service, supervision and handling of violations in the medical device sector.
  • Existing medical device regulations: the Medical Equipment Regulations. Some of its articles are still cited in public service guidance issued by the competent authority or medical universities, for example qualification of the technical person in charge, restrictions on importing second-hand devices, and approval of refurbished equipment.
  • Implementation directives of the competent authority: including specific directives on foreign manufacturer representative registration, importer and distributor licensing, product registration, risk classification, technical requirements, commodity identification, labeling, warehousing and after-sales service.
  • Electronic system requirements: the current workflows, forms, commodity identification and traceability requirements in the IMED and TTAC systems, which must also be verified in actual project execution.

The third edition of the Medical Device Registration Guideline (December 2018) cited in the original source can serve as a reference for organizing technical documentation, but this review could not confirm that it remains the single valid document covering all current requirements. Formal submissions should follow the current directives and system requirements.

Q3: How are medical devices classified in Iran? Are the 16 categories mentioned in the original source accurate?

Answer: Iran applies a four-tier risk classification of Class A, B, C and D, generally from Class A (low risk) to Class D (high risk). Classification should be determined based on the manufacturer’s intended use, site of use, mode and duration of contact, invasiveness, whether the device is active, product technical characteristics and the applicable classification rules.

The 16 classification rules mentioned in Iranian classification materials are not the same concept as product catalogs or business-area categories. The original source listed 16 areas such as “clinical chemistry and toxicology, blood and pathology, immunology and microbiology”; this review could not verify those areas as the statutory risk classification structure in current public classification guidance. It is recommended to delete them or provide a separate catalog basis, and they must not be mixed with the A-D risk classification.

In practice, the Iranian classification must not be presumed solely from the product name or the classification result of another country. The product’s intended use, principle of operation, mode of contact and model composition should first be checked, and the risk class should then be confirmed through the current IMED process by the local filing entity.

Q4: How big is the difference in filing workload between Class A and Class D products?

Answer: The higher the risk class, the more safety, performance and clinical evidence is usually required, but it is not accurate to say that Class A only requires a declaration of conformity, or that Class D products always require a full clinical trial or a technical dossier exactly identical to CE MDR.

The documentation requirements for imported products in Iran are also affected by country-of-manufacture grouping, product type, existing approvals, quality systems and technical review results. For example, the current technical requirements impose pre-registration production line audits for certain Class C and D products manufactured in G3/G4 countries.

Therefore, requirements should be confirmed for the specific product and country of manufacture; the full filing workload must not be inferred from the A-D classification alone.

Q5: Can a foreign manufacturer apply for registration in Iran directly? Must a local company hold the registration?

Answer: A foreign manufacturer needs to carry out the relevant registration and import activities through a compliant local entity in Iran. The competent authority has established a representative registration procedure for foreign manufacturers, and the foreign manufacturer should register its representative relationship as required and process import authorizations through a qualified Iranian local importer.

Three concepts need to be distinguished here:

  • Foreign manufacturer representative: acts on behalf of the foreign manufacturer in Iran for specified matters under a written authorization. The representative authorization documents should be authenticated as required by Iran.
  • Iranian importer: must hold the corresponding local business and import licenses and bears responsibility for product import, import authorization and related compliance.
  • Product IRC: assigned by the competent authority to each approved registered product record; it is the product registration identification code and must not be simply equated with the importer’s business license or with the customs clearance permit for each shipment.

The 2018 Regulations on Activities in the Field of Medical Equipment define manufacturers, importers and legal representatives separately and set out authentication requirements for the authorization documents of foreign company representatives. It is therefore inappropriate to describe all of these roles collectively as “a local agent holding the registration certificate”. Before project launch, verify under which entity and system account the representative registration, the product IRC and the import authorization are respectively held.

Q6: What steps are usually required from preparation to product import?

Answer: Plan in the following order; specific steps may vary by product category, importer and the division of work within the competent authority:

  • Confirm the product scope and risk class: clarify intended use, models, product composition, manufacturer and manufacturing site.
  • Check import policy: confirm whether the product is subject to import controls, market regulation or special approval restrictions.
  • Identify the Iranian local partner: verify the legal qualifications of the foreign manufacturer representative registration entity and the importer.
  • Complete entity and representative registration: establish the company profile per current IMED requirements, register the foreign manufacturer representative relationship, and confirm requirements such as the technical person in charge.
  • Prepare product documentation: compile the technical dossier, certificates, quality system, labels, catalogs and proof of sale per the product risk class and applicable technical directives.
  • Submit the product registration application: submit the documents in the relevant IMED system and complete the review, rectification and product IRC code process as required.
  • Obtain import authorization and clear customs: after product registration, the importer must still obtain the corresponding import license as required and complete order registration, foreign exchange and customs formalities.
  • Complete commodity identification and traceability: complete GTIN, commodity identification and TTAC traceability processes per applicable requirements.
  • Post-market maintenance: continuously handle complaints, quality issues, changes, recalls, after-sales service and registration information updates.

Special note: Iranian regulations explicitly state that establishing a company profile does not constitute product quality approval or product registration, and product registration does not constitute an import and customs clearance license.

Part 2: Registration Validity, Timeline, Fees and Filing Documents

Q7: How long is a product IRC valid? When is renewal required?

Answer: The original statement that “the registration certificate is uniformly valid for 4 years and should be renewed 90 days before expiry” should not be continued. The current public information retrieved in this review does not support a uniform 4-year validity period with renewal 90 days in advance for all imported medical devices.

The valid status of an Iranian product IRC may be linked to the related approval documents, quality system certificates, foreign manufacturer representative authorization and the registration information held by the competent authority. Public service guidance from Iran University of Medical Sciences also lists situations that may cause an IRC to become invalid, such as expiry of related certificates, expiry of the manufacturing license or expiry of committed plans.

A further distinction is needed between the local manufacturing license and the imported product IRC: Article 42 of the 2018 Regulations on Activities in the Field of Medical Equipment provides that a manufacturer should submit renewal documents at least two months before the expiry of the manufacturing license. That article cannot be directly applied to all imported product IRCs.

In project execution, follow the validity period displayed in the IMED system and the specific requirements of the competent authority for the product, and check in advance the validity of the representative authorization, authentication and quality system documents.

Q8: How long does the official review take in Iran? How long does the whole project take?

Answer: There is currently insufficient basis to treat “60-120 working days” as a uniform official review timeline applicable to all products.

Public IRC review process materials from Iran University of Medical Sciences indicate that for certain Class A and B products handled by that university, the published review time is approximately 15-20 working days. However, that time corresponds only to a specific delegated review step and does not represent all categories, the full rectification process, or the overall timeline from project launch to obtaining an import license.

The overall project timeline is also affected by the following factors:

  • product category and the actual acceptance path of the competent authority;
  • registration progress for the foreign manufacturer representative and the importer;
  • applicability of CE, FDA and Japanese approvals and ISO 13485 and other certificates;
  • whether a production line audit, clinical or other supplementary evidence is required;
  • document rectification, translation and authentication, import licensing, order registration and foreign exchange arrangements.

Therefore, formal quotations or project plans should list “document preparation time, official review time, rectification time, import licensing and customs clearance time” separately; industry experience estimates must not be presented as official commitments.

Q9: What are the official fees for medical device registration in Iran?

Answer: The original figures of “about USD 2,500 per product and USD 500 per import license batch” could not be supported by any reliable basis as the current uniform official fee standard and should be deleted.

Relevant provisions of Article 4 of the Regulations on Activities in the Field of Medical Equipment make clear that the competent authority may charge fees for product registration, source registration, import licenses, clearance licenses and the issuance or renewal of related permits. However, this review could not verify from the official public pages consulted a uniform current amount applicable to all types of imported products.

Actual projects should follow the fee amounts in Iranian rials currently displayed in IMED or the relevant government systems, and verify with the local importer whether there are additional fees for entity registration, representative registration, commodity identification, testing, authentication and agency services. Currency conversion at exchange rates is for budget reference only and must not be published as an official USD fee standard.

Q10: What documents are usually required for importing medical devices?

Answer: Document requirements depend on the product risk class, country of manufacture and applicable technical directives. Based on the publicly available product IRC review process in Iran, prepare at least the following modules:

Group 1: Manufacturer and entity documents

  • Legal name, registered address and country of manufacture of the manufacturer;
  • Information on the Legal Manufacturer and the OEM / actual production site;
  • Foreign manufacturer authorized representative documents and the authentication completed as required;
  • Entity registration and licensing documents of the Iranian local representative and importer.

Group 2: Product identification documents

  • Product name, models, specifications and product catalog;
  • Product labels, packaging and product photos;
  • REF and Product / Catalogue Number;
  • GTIN and product identification information;
  • Product intended use, working principle, structural composition and scope of application.

Group 3: Safety and performance evidence

  • Product technical documentation;
  • Applicable CE, FDA or Japanese approval certificates;
  • Manufacturer’s Declaration of Conformity (DoC, provided per the applicable class and requirements);
  • ISO 13485 quality management system certificate;
  • Applicable safety, performance, testing and clinical evidence.

Group 4: Evidence of market sale

  • Proof of sale or registration of the product in the country of manufacture;
  • Product sales history as required, including years, countries and sales volumes;
  • For products manufactured in China, prepare materials such as Chinese registration or proof of sale according to the actual review requirements.

Group 5: Import and localization documents

  • Importer and representative registration information;
  • Product labels, instructions for use and packaging documents;
  • Translation, authentication and other supplementary documents required by the competent authority.

Note: Not every item applies unconditionally to all products. The specific document list should follow the current product registration section of the IMED system, the risk class and the requirements of local reviewers.

Q11: Are CE or FDA certificates mandatory in Iran? Can a Chinese NMPA certificate substitute?

Answer: CE or FDA must not be described as a single uniform requirement applying identically to all Class B, C and D products, and an NMPA registration certificate must not be assumed to directly substitute for the international approvals required by Iran.

The current Iranian product registration technical requirements involve the following certificates:

  • CE: check the scope and level of notified bodies accepted by the Iranian competent authority; do not rely on the mere presence of a CE mark.
  • US FDA: depending on the applicable product pathway, this involves 510(k) or PMA and the corresponding registration evidence.
  • Japan: may involve approval or proof of sale issued by the Japanese competent authority.
  • Class A products: public review process materials from Iran University of Medical Sciences show that the manufacturer’s Declaration of Conformity can serve as a key document, and CE is a favorable certificate in some Class A reviews; it is not mandatory in all cases.
  • Chinese NMPA: may serve as proof of registration or sale in China, the country of origin, per specific review requirements, but it cannot be treated as a direct equivalent of CE, FDA or Japanese approval, nor does it exempt the product from independent review in Iran.

In addition, some technical requirements also address proof of sale in the country of origin, the sales history of Class C/D products in the EU, the US or Japan, and the quality system and production line audit requirements associated with country-of-manufacture grouping.

Therefore, before filing, first check the product risk class, country of manufacture, Legal Manufacturer, OEM and the actual coverage of the certificates held, and then determine the combination of approval documents to provide.

Part 3: Import Release and Post-Market Obligations

Q12: Can a product be imported and sold directly once an IRC is obtained?

Answer: No. An IRC is a product registration identification code and is not an import license or a customs release.

Article 4 of the Regulations on Activities in the Field of Medical Equipment explicitly provides that product registration and related permits do not automatically constitute import and customs clearance authorization, and the relevant products must still obtain import licenses separately as required.

The following should also be checked at the import stage:

  • whether the Iranian importer holds the corresponding license;
  • whether the product IRC is in a valid state;
  • whether the import license required for this import has been obtained;
  • whether order registration and the applicable foreign exchange arrangements have been completed;
  • whether the applicable commodity identification, GTIN and TTAC traceability requirements have been completed;
  • whether the product labels, packaging, quantities, models and filing documents are consistent.

All products must not be described collectively as “re-registered in the same way for each import batch”. Whether batch-level approval or other release formalities are required should be judged per the product category, the import authorization and the specific requirements of the competent authority for that product.

Q13: Which medical devices may not be importable? Are second-hand and refurbished devices allowed?

Answer: Iran applies market management and product quality control requirements to medical device imports. Article 4 of the 2018 Regulations on Activities in the Field of Medical Equipment allows the competent authority to take import control measures for reasons such as market regulation, so obtaining an IRC does not mean the product can be imported without restriction at any time.

The original claim that “the IFDA exclusion list covers more than 1,400 devices” could not be verified in terms of its current version, scope of application or specific legal basis; this definite figure should be deleted. At project initiation, verify the current import policy with the Iranian importer and the competent authority based on the product name, model, commodity code and local substitution situation.

Regarding second-hand and refurbished devices, a distinction is needed:

  • Second-hand devices: under Article 47 of the Medical Equipment Regulations, importing second-hand medical devices for the purpose of sale, use or consumption is prohibited.
  • Refurbished or remanufactured devices: under Article 48, devices refurbished or remanufactured by the original manufacturer or its authorized entity may be applied for import when they comply with the relevant directives, obtain Technical Committee approval and fall within the currently permitted scope.

Refurbished devices are therefore not prohibited across the board, nor can it be understood that they may be imported whenever there is an urgent need. Follow whether the specific product is within the permitted scope and whether approval has been obtained.

Q14: What happens if a change occurs after product registration?

Answer: Change handling should be judged per the product type, the change content and the applicable current directives. The unverified uniform “major change / minor change” division and all of its examples in the original source should not be continued.

For locally manufactured products, Article 41 of the 2018 Regulations on Activities in the Field of Medical Equipment provides that a manufacturer should notify the competent authority of changes in materials, production components, software, hardware or production processes; if the authority determines that a change materially affects product safety, performance or the production method, re-registration of the relevant information and a new license may be required.

For imported products, the manufacturer and the local representative should focus on checking:

  • whether the Legal Manufacturer or OEM has changed;
  • whether the manufacturing address, production site or sterilization site has changed;
  • whether models, REF, GTIN and specifications have changed;
  • whether intended use, working principle, materials and key performance have changed;
  • whether certificates such as CE, FDA, Japanese approval or ISO 13485 have been updated;
  • whether the foreign manufacturer representative authorization has changed or expired.

Before implementing a change, first verify the current change filing path in IMED and whether prior approval is required, through the local representative. Failure to declare changes as required may result in suspension, invalidation or revocation of the product IRC or related licenses.

Q15: What mandatory post-market obligations apply in Iran?

Answer: Post-market obligations are not limited to adverse event reporting; they also include product quality management, complaint handling, after-sales service, supervision and inspection, and recalls.

Based on the relevant Iranian regulations and the public systems of the competent authority, companies should focus on:

  • Quality issue and adverse event reporting: the Iranian medical device competent authority operates an MDR (Medical Device Reporting) channel for quality issue reports and publishes the related reporting and complaint handling procedures.
  • Complaint and quality issue handling: manufacturers, importers and legal representatives should cooperate with investigations by the competent authority and retain related handling records.
  • Post-market surveillance: the authority may check through sampling, quality testing and supervised evaluation whether products continue to meet the safety and performance requirements at the time of filing.
  • Recalls and corrective actions: when a product has a major safety or performance nonconformity, the manufacturer, importer or its legal representative should report and carry out recalls or corrective actions as required.
  • After-sales service: manufacturers, importers and their legal representatives bear the corresponding after-sales obligations. For capital equipment, Article 53 of the regulations provides for a product warranty of at least one year and requires continued after-sales service for ten years after the warranty period, or a corresponding service arrangement as required; implementation should also follow the relevant directives.

This review could not confirm from the official materials consulted the uniform claim that “a final report must be submitted within one month for all adverse events”, nor verify that the email address listed in the original source is the only valid reporting channel. It is recommended to delete that fixed deadline and the unconfirmed contact information, and follow the current IMED MDR process and the specific reporting requirements for each event.

Q16: Will Iran conduct on-site audits of overseas factories of Chinese manufacturers?

Answer: It is no longer accurate to state generally that “on-site factory inspections abroad are generally not required under the current system”.

The Iranian medical device registration technical requirement materials retrieved in this review impose different requirements by country-of-manufacture grouping and risk class. In particular, Class C and D products manufactured in G3/G4 countries are subject to pre-registration production line audit requirements, while Class A and B products involve requirements such as ISO 13485 certificates issued by qualified organizations.

In the country grouping of those technical requirements, products manufactured in China need careful verification of whether the G4 grouping applies. If a product is Class C or D, confirm early in the project whether a production line audit is required, the auditing body, the audit scope, the on-site or remote format and the cost arrangements.

Meanwhile, the 2018 Regulations on Activities in the Field of Medical Equipment also provide post-market surveillance, sampling and testing, and quality inspection mechanisms. Therefore, even if a product did not trigger an overseas production line audit at registration, this does not mean its production system will not be subject to subsequent regulatory oversight.

Note: The specific applicability of production line audits should be verified with IMED by the Iranian local representative against the currently effective technical directives and product-specific requirements.

Part 4: Filing Risks, Sanctions and Agency Relationships

Q17: What are the common documentation problems in Iranian medical device registration?

Answer: Based on the public IRC review process and documentation requirements, companies should avoid the following problems in particular:

  • inaccurate product name, risk class or product catalog selection;
  • inconsistent information on the Legal Manufacturer, OEM and actual production address;
  • models, REF or Product / Catalogue Number inconsistent with labels, catalogs or the official website;
  • CE, FDA, Japanese approval or ISO 13485 certificates not matching the filing manufacturer, or with insufficient validity;
  • proof of sale or sales history in the country of origin not provided as required;
  • GTIN entered incorrectly or in duplicate, or incomplete product identification information;
  • foreign manufacturer representative authorization documents not authenticated as required, or the representative registration expired;
  • product IRC valid, but importer qualifications, import license, commodity identification or traceability steps not completed.

Among these, models, manufacturer identity, certificate coverage, GTIN and proof of sale are all explicitly examined in the public review process. At project launch, first establish the mapping of “manufacturer – production site – model – certificate – GTIN” to avoid repeated rectification after submission.

Q18: Is exporting medical devices to Iran feasible under international sanctions?

Answer: The question cannot be answered with a simple “yes” or “no”; it must be assessed item by item based on the exporting country, product attributes, transaction parties, payment routes and logistics arrangements.

On US sanctions:

Section 560.530 of the US Iranian Transactions and Sanctions Regulations (31 CFR Part 560) establishes a general license arrangement for medical devices meeting the definition, but not all medical devices, all counterparties and all transaction activities are automatically authorized.

According to OFAC public FAQs 318, 319 and 483:

  • medical devices meeting the definition may benefit from the relevant authorization when the general license conditions are met;
  • products on the list of medical devices requiring specific authorization need further specific authorization;
  • exports to procurement parties of military, intelligence or law enforcement bodies, and to certain sanctioned persons, are not automatically covered by the general license;
  • exporters remain responsible for due diligence on the transaction counterparties.

On financial risks in 2026:

On October 5, 2026, OFAC issued a risk advisory to foreign financial institutions continuing to do business with Iranian financial institutions, noting that such institutions may face sanctions risk. This means that even if the product itself may qualify under the medical device general license, banks may still refuse to process related transactions or require stricter compliance review.

Therefore, before project launch, check at least:

  • whether the product falls within the medical device general license and whether it is on the specific authorization list;
  • whether the manufacturer, Iranian importer, end users and actual controllers are subject to any sanctions lists;
  • whether the paying bank, correspondent banks and settlement currency can accept the transaction;
  • whether carriers, insurers, transshipment locations and related service providers are subject to restrictions;
  • whether the product is also subject to export controls of the exporting country or other jurisdictions.

The medical device humanitarian or general license must not be understood as unrestricted payment, transport, insurance and services. Where US persons, US-origin products or USD clearing are involved, transaction review should be performed by professionals familiar with the relevant sanctions regulations.

Q19: If the Iranian local representative or importer is replaced, can the product registration be transferred directly?

Answer: It cannot be categorically promised that “changing the agent always requires re-registration”, nor guaranteed that “only the representative needs to be changed and all IRCs are retained”. The public regulations and service materials retrieved in this review are insufficient to prove that a uniform, automatic registration transfer procedure exists for all products.

The following need to be confirmed separately:

  • whether the foreign manufacturer representative relationship can be changed, and what authorization and supporting documents are required;
  • how the previous importer’s import license, company profile and product identification information will be handled;
  • whether the product IRC can continue to be used, and whether re-review or an update is required;
  • who will take over imported products, inventory, after-sales service, complaints and recall responsibilities.

The following should be agreed in advance in the cooperation agreement:

  • Right to use registration documents: the manufacturer has the right to obtain and use the registration documents and filing records related to its own products;
  • Cooperation on termination of the representative relationship: the previous representative should cooperate in submitting representative change, authorization revocation or other necessary applications;
  • Handover of data and records: including IRC information, import license records, model and GTIN data, complaint and after-sales records;
  • Inventory and after-sales arrangements: clarify responsibilities for goods in transit, imported inventory, warranty, repair, complaints and recalls;
  • Prohibition of improper obstruction: explicitly state that the manufacturer’s documents must not be withheld or the manufacturer’s lawful replacement of partners obstructed without justifiable reasons.

Contract terms can reduce the commercial risk of agency relationship changes, but they cannot replace approvals by the competent authority. Before signing, have an Iranian local professional entity confirm the specific change and transfer path.

Q20: What should Chinese companies verify before entering the Iranian market?

Answer: Complete the following seven checks before project initiation:

  • Does the product fall within the scope of Iranian medical device regulation, and are the risk class and intended use clear?
  • Is the product subject to current import policy, market regulation or special approval restrictions?
  • Can the foreign manufacturer representative be registered as required, and does the Iranian importer hold valid qualifications?
  • Are the Legal Manufacturer, OEM, manufacturing site, models and certificates consistent with one another?
  • Do CE, FDA, Japanese approvals, ISO 13485, proof of sale in the country of origin and other technical documents meet the requirements for the product?
  • Are the IRC, import license, GTIN, commodity identification and TTAC traceability processes already clear?
  • Are there enforceable arrangements for sanctions screening, bank payments, logistics, after-sales service, complaint reporting and recall responsibilities?

If any of these seven items lacks a clear conclusion, large-scale investment should not be launched merely on the basis that “the local agent says registration is possible”. First verify product access, import execution and the business cooperation structure separately, then set the registration plan and budget.

Appendix 1: Main regulations and public sources referenced in this article

  • Regulations on Activities in the Field of Medical Equipment, approved on 1 Dey 1397 of the Iranian calendar. Regulation text and articles: https://www.irancodify.com/b/%D8%A2%DB%8C%DB%8C%D9%86_%D9%86%D8%A7%D9%85%D9%87_%D9%81%D8%B9%D8%A7%D9%84%DB%8C%D8%AA_%D8%AF%D8%B1_%D8%AD%D9%88%D8%B2%D9%87_%D8%AA%D8%AC%D9%87%DB%8C%D8%B2%D8%A7%D8%AA_%D9%BE%D8%B2%D8%B4%DA%A9%DB%8C_%D9%85%D8%B5%D9%88%D8%A8_1397-10-01
  • Public IRC review process materials from Iran University of Medical Sciences (review process for certain Class A and B products): https://imed.iums.ac.ir/uploads/66/%D8%B5%D8%AF%D9%88%D8%B1%20%D9%85%D8%AC%D9%88%D8%B2/%D9%81%D8%B1%D8%A7%DB%8C%D9%86%D8%AF_%D8%B5%D8%AF%D9%88%D8%B1_%DA%A9%D8%AF_IRC.pdf
  • Public service materials of the food and drug department of Iran University of Medical Sciences: including product IRC, GTIN, manufacturer information, certificates, commodity identification, TTAC and related FAQs: https://gservice.mui.ac.ir/fa/node/1418
  • Technical requirements for imported products published by the food and drug department of Tehran University of Medical Sciences: https://fdo.tums.ac.ir/uploads/282/2023/Sep/11/file12.pdf
  • Iran Food and Drug Administration medical device portal: https://www.imed.ir/
  • Iran Food and Drug traceability system TTAC: https://www.ttac.ir/
  • OFAC official Iran sanctions page: https://ofac.treasury.gov/sanctions-programs-and-country-information/iran-sanctions
  • OFAC FAQ 318: the medical device general license does not cover all medical devices. https://ofac.treasury.gov/faqs/318
  • OFAC FAQ 319: the medical device general license does not apply to all Iranian transaction parties. https://ofac.treasury.gov/faqs/319
  • OFAC FAQ 483: medical devices requiring specific authorization and related export requirements. https://ofac.treasury.gov/faqs/483
  • OFAC risk advisory to foreign financial institutions, October 5, 2026: https://ofac.treasury.gov/media/937091/download?inline=
  • OFAC notice on suspension of certain general licenses, September 8, 2026: https://ofac.treasury.gov/media/936886/download?inline=

Regulatory verification note

  • The verification date of this article is November 11, 2026.
  • The formal legal effect of Iranian regulations is determined by the Persian original text, subsequent amendments and the currently effective directives of the competent authority.
  • For fees, timelines, label language details and case-specific transfer procedures that could not be confirmed through official public pages, this article has deliberately avoided presenting them as uniform mandatory requirements.
  • The registration technical requirements and local implementation processes described in this article should be verified with IMED by the Iranian local representative for the applicable version before filing a specific product.
  • This article does not constitute legal advice on Iran, export control advice or sanctions compliance advice.
Grzan

Author:Grzan

Get the latest global medical device development and regulatory news, insights and resources.

WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail